At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
enzastaurin +1 moredrug
Likely dose
enzastaurin 1125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer
In Brief
A Phase 2 clinical trial evaluating enzastaurin and placebo for Non Small Cell Lung Cancer and Small Cell Lung Cancer. Completed, enrolled 109 participants across 7 sites in 5 countries.
Detailed Summary
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, Small Cell Lung Cancer
CountriesDenmark, Norway, Poland, Romania, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionJan 2011
TodayJul 2026
First PostedDec 22, 2006
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.5 years ago
Interventions
enzastaurindrug
1125 mg loading dose then 500 mg, oral, daily, until disease progression
placebodrug
oral, daily